SPTX

The company's therapeutic candidates are aimed at conditions such as depression and anxiety disorders. All of the candidates currently in development are built on the company's proprietary Glyph technology platform. This platform is designed to improve how these medicines behave in the body. Specifically, it is intended to enable oral bioavailability, meaning the drugs can be absorbed effectively when taken by mouth, and to allow them to bypass first-pass metabolism in the liver. The platform is also designed to reduce liver enzyme elevations, hepatotoxicity, and other side effects that can limit the use of certain treatments.

Because every candidate in Seaport Therapeutics' pipeline is based on the Glyph platform, the technology is central to the company's strategy and its approach to drug development. As a clinical-stage business, the company is focused on advancing these candidates through testing rather than selling approved products. It works with clinicians and key opinion leaders within the healthcare and neuropsychiatric medicine fields, drawing on their expertise as it develops its programs. This focus on a single underlying platform applied across multiple neuropsychiatric conditions defines how Seaport Therapeutics organizes its research efforts and its long-term development plans.